trending Market Intelligence /marketintelligence/en/news-insights/trending/srep4ociwlpayhddmzvbkw2 content esgSubNav
In This List

Invion to spin out 2 respiratory drugs into new company

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Invion to spin out 2 respiratory drugs into new company

Australia-based Invion Ltd. will spin out two drugs for chronic airway disease and all shares in its unit Invion Inc. into a new company.

The new entity, called Chronic Airway Therapeutics Ltd., is a stand-alone, public and unlisted company, also based in Australia. It will develop the products, called INV102, or nadolol, and INV104, or zafirlukast, in China, with plans to advance into late-stage clinical trials in 2019.

Invion said the demerger will provide a separate structure for each entity to fund and advance their clinical development programs, maximizing shareholder value.

Eligible Invion stockholders can receive Chronic Airway Therapeutics shares on a 1-for-1 basis.

Additionally, drug developer Invion appointed Chief Medical Officer and Executive Director Mitchell Glass as executive director of Chronic Airway Therapeutics.

The Cho Group agreed to loan Chronic Airway Therapeutics at least $200,000 in funding. The Hong Kong-based investor, along with its associates, owns 68.16% of Invion.

The demerger, which is expected to close in late October, remains subject to shareholder and regulatory approvals.